[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100443761":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":42,"responsibleParty":60,"collaborators":62,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":25,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":77,"minAge":78,"maxAge":25,"enrollmentInfo":79,"targetDuration":25,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"University of Alberta","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Midodrine","EXPERIMENTAL","Midodrine 10 mg PO\u002FNG q8h",[13],"Drug: Midodrine",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Microcrystalline cellulose PO\u002FNG q8h",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","10 mg PO\u002FNG q8h",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Microcrystalline cellulose PO\u002FNG 18h",[15],[30],{"name":31,"affiliation":5,"role":32},"Oleksa Rewa, MD","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Dawn Opgenorth, RN","CONTACT","780 492-4698","dawno@ualberta.ca",{"name":31,"role":36,"phone":40,"phoneExt":25,"email":41},"780 492-6621","rewa@ualberta.ca",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"University of Alberta Hospital","RECRUITING","Edmonton","Alberta","T5R 0T1","Canada","CA",{"type":52,"coordinates":53},"Point",[54,55],-113.46871,53.55014,{"lat":55,"lon":54},[58,59],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},{"name":31,"role":36,"phone":40,"phoneExt":25,"email":41},{"type":61,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[63,65,67],{"name":64,"class":6},"University Hospital Foundation",{"name":66,"class":6},"Institute of Health Economics, Canada",{"name":68,"class":6},"Alberta Health services","100443761","phase-4-midodrine-for-the-early-liberation-of-vasopressor-support-in-the-icu-liberate-multi-site-100443761",false,"NCT05058612","Midodrine for the Early Liberation of Vasopressor Support in the ICU (LIBERATE Multi-Site)","Midodrine for the Early Liberation From Vasopressor Support in the ICU - The LIBERATE Multi-Site Study","Inclusion Criteria:\n\n* Age \\> 18 years\n* Ongoing vasopressor support\n* Decreasing vasopressor dose(s)\n\nExclusion Criteria:\n\n* Greater than 24 hours from peak vasopressor dose\n* Contraindication to enteral medications\n* Previously received midodrine in last 7 days\n* Expected death or anticipated withdrawal of life-sustaining therapies in next 24 hours\n* Pregnancy\n* Known allergy to midodrine",true,"ALL","18 Years",{"count":80,"type":81},870,"ESTIMATED","INTERVENTIONAL",[84],"PHASE4","Vasopressors are medications that are given intravenously to increase the blood pressure of patients with illnesses that cause dangerous blood pressure drops. When a doctor prescribes a vasopressor, they ask that the dose be adjusted to achieve a specific blood pressure. This kind of medical support with intravenous (IV) vasopressors are usual treatments in intensive care unit (ICU) settings. Oral vasopressors, such as midodrine, have been historically used to maintain blood pressure in non-critically ill patients. In this study, the investigators will be using midodrine to reduce the need for IV vasopressors as blood pressure improves during the stay in the ICU.\n\nThis LIBERATE multi-site study will continue the work of the LIBERATE feasibility RCT study to evaluate the role of midodrine for patients with low blood pressure in the ICU. It is comprised of the multi centre pilot RCT followed by the definitive multi centre RCT.",[87],"Vasoplegia",[89,90,91,92],"critical care medicine","intensive care","shock","midodrine","2026-01-15",{"date":95,"type":96},"2026-01-20","ACTUAL",{"date":98,"type":96},"2021-03-22",{"date":100,"type":81},"2028-02",{"name":5,"class":6},1]